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Environmental exposure to hormonally active
chemicals has coincided with an increase in
the incidence in breast cancer (Davis et al.
1993), testicular cancer (Skakkebaek et al.
1998), and other endocrine-related diseases
(Sharpe and Skakkebaek 1993). These out-
comes are thought to result from extempora-
neous exposure to synthetic estrogens during
fetal development (Sharpe and Skakkebaek
1993) and have motivated the worldwide for-
mation of government-sponsored committees
to evaluate evidence for this hypothesis. For
instance, in the United States, the U.S.
Environmental Protection Agency (EPA)
developed a screening program to test chemi-
cals that may contaminate water and food to
assess potential endocrine disruptor activity
(Endocrine Disruptor Screening and Testing
Advisory Committee 1998).
At the request of the U.S. EPA, the
National Toxicology Program (NTP) con-
vened a meeting to consider whether environ-
mentally relevant doses of endocrine disruptors
caused biological effects. In 2001, the NTP
Low-Dose Peer Review Panel published a ﬁnal
report (NTP 2001), which stated that there
was “credible evidence for low-dose effects”
and suggested that different experimental ani-
mal strains may account for reports of both
positive and negative effects for the same para-
meters. In this regard, Spearow et al. (1999)
observed that rodent strains selected for high
fecundity and rapid growth rates, such as
CD-1 mice, are more estrogen resistant than
the less fecund C57Bl6.
An additional controversy identified by
the NTP was the shape of the dose–response
curve, which was reported as nonmonotonic
for some effects of prenatal xenoestrogen
exposure. For example, prenatal methoxy-
chlor exposure altered the response of the
adult uterus to 17β-estradiol (E2); low doses
increased uterine weight, and higher doses
reduced it (Alworth et al. 2002). This type of
nonmonotonic response was also observed for
other end points with other estrogenic chemi-
cals (Rubin et al. 2001; Vandenberg et al.
2006; vom Saal et al. 1997), arguing that
low-dose effects cannot be deduced from
effects observed at high doses. 
Our research focuses on the effects of peri-
natal exposure to environmentally relevant
levels of the xenoestrogen bisphenol A (BPA).
In the the present study we examined strain
sensitivity and the shape of the estrogen
dose–response curve in the context of our
ongoing work in the mouse mammary gland.
In addition, we explored the effects of peri-
natal BPA exposure on subsequent estrogen
sensitivity at puberty. 
BPA, a compound used in the manufac-
ture of polycarbonate plastics and epoxy resins,
leaches from food and beverage containers
(Biles et al. 1997; Brotons et al. 1994) and
dental sealants and composites (Olea et al.
1996) under normal conditions of use
(Markey et al. 2001b, 2003b). BPA levels have
been measured in human urine (Calafat et al.
2005), serum (Takeuchi and Tsutsumi 2002),
and maternal and fetal plasma, amniotic ﬂuid,
and placental tissue at birth (Ikezuki et al.
2002; Schonfelder et al. 2002). We chose to
administer perinatally 0 or 250 ng BPA/kg
body weight (bw)/day to mice. Based on data
reported by Arakawa et al. (2004), we esti-
mated that this level of BPA should fall within
the range of reported human exposures.
In the mammary gland, perinatal exposure
to BPA alters ductal invasion of the stroma at
puberty and increases lateral branching and the
number of terminal ends during adulthood
(Markey et al. 2001a; Munoz de Toro et al.
2005). Although the mechanisms by which
BPA induces developmental abnormalities in
the mammary gland are unknown, it is plausi-
ble that estrogen receptors (ER), which are
expressed in the fetal mammary gland, may
mediate BPA-induced effects. 
In the present study, we compared the
response of the mammary glands to E2 in
outbred CD-1 mice (the strain we have used
previously) with inbred C57Bl6 mice, which
have been used in numerous studies involv-
ing development of the mammary gland.
Different levels of biological complexity
within the mammary gland (i.e., tissue orga-
nization and gene expression) were examined.
We also examined the effects of perinatal
BPA exposure on the response to E2 at
puberty in both strains.
Materials and Methods
Animals. CD-1 (Crl: CD-1; Charles River
Laboratories, Wilmington, MA) and C57Bl6
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BACKGROUND: Studies of low-dose effects of xenoestrogens have yielded conﬂicting results that may
be attributed to differences in estrogen sensitivity between the rodent strains examined. Perinatal
exposure of CD-1 mice to low doses of the xenoestrogen bisphenol A (BPA) alters peripubertal
mammary gland development. Future studies to assess the role of estrogen receptors as mediators of
BPA action require estrogen receptor knock-out mice that were generated on a C57Bl6 back-
ground. The sensitivity of the C57Bl6 strain to estradiol and BPA is unknown. 
OBJECTIVES: In the present study we examined whether the mammary glands of CD-1 and C57Bl6
mice exhibited similar responses to 17β-estradiol (E2) and whether perinatal exposure to BPA
equally enhanced sensitivity of the mammary glands to E2 at puberty. 
METHODS: Immature mice were ovariectomized and treated for 10 days with one of eight doses of
E2. Morphological mammary gland parameters were examined to identify doses producing half-
maximal effects. Mice were exposed perinatally to 0 or 250 ng BPA/kg body weight (bw)/day from
gestational day 8 until postnatal day (PND) 2. On PND25, female offspring were ovariectomized
and given an estrogen challenge of 0, 0.5, or 1 µg E2/kg bw/day for 10 days. Morphometric para-
meters of the mammary gland were compared between strains. 
RESULTS: Both strains exhibited similar responses to E2. Perinatal BPA exposure altered responses
to E2 at puberty for several parameters in both strains, although the effect in CD-1 was slightly
more pronounced. 
CONCLUSION: Both mouse strains provide adequate models for the study of perinatal exposure to
xenoestrogens.
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strains, nonmonotonic response, uterotropic assay. Environ Health Perspect 115:592–598 (2007).
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Maine) mice were housed in the Tufts-New
England Medical facility under temperature
and light controlled (14-hr light and 10-hr
dark) conditions. Food (Rodent Diet 2018;
Harlan Teklad, Madison, WI), cages, and
bedding tested negligible for estrogenicity by
the E-SCREEN assay (Soto et al. 1992); water
was supplied in glass bottles. All experimental
procedures were approved by the Tufts
University–New England Medical Center
Animal Research Committee. All animals were
treated humanely and with regard for allevia-
tion of pain in accordance with the Guide for
Care and Use of Laboratory Animals (Institute
of Laboratory Animal Resources 1996).
To study the response to various doses of
E2, female mice (n = 5/dose for each strain)
were ovariectomized on postnatal day
(PND) 25 under isoflurane anesthesia, and
Alzet osmotic pumps (Alza Corp., Palo Alto,
CA) were implanted subcutaneously as previ-
ously described (Vandenberg et al. 2006). The
pumps were ﬁlled with solutions delivering 0,
0.25, 0.5, 1, 2.5, 5, 10, or 50 µg E2/kg bw/day
(Steraloids Inc., Newport, RI) dissolved in
50% dimethylsulfoxide (DMSO; vehicle con-
trol; Sigma-Aldrich, St. Louis, MO) for the
length of treatment. The mice were killed on
PND35, and their mammary glands and uteri
were collected. For positive controls, we used
the range of E2 doses previously reported in a
mouse mammary gland assay by Skarda (2002)
and a mouse uterotrophic assay (Padilla-Banks
et al. 2001) based on the wet weight of the
uterus (a standard for estrogen exposure).
To study the effects of perinatal exposure
to BPA on responses to E2, male and female
mice of each strain were paired. The morning
on which a vaginal plug was observed was
designated day 1 of pregnancy. On the
evening of day 8 of pregnancy, dams were
weighed and implanted subcutaneously with
Alzet osmotic pumps releasing either vehicle
(50% DMSO) or 250 ng BPA/kg bw/day
(Sigma-Aldrich) dissolved in vehicle. For 
convenience, we refer to these groups as
0BPA and 250BPA, respectively. The pumps
delivered BPA or vehicle until PND2. The
offspring were culled to eight pups per dam
on PND1. On PND25, three pups from each
litter were ovariectomized, and pumps
administering vehicle (50% DMSO) or 0.5 or
1µ g  E 2/kg bw/day were implanted subcuta-
neously. These females were weighed and
killed on PND35 (CD-1: n = 9–11/treatment
group; C57Bl6: n = 6–7/treatment group).
Tissue collection. The fourth inguinal
mammary glands were dissected out; one
mammary gland was immediately immersed
in RNAlater (Ambion Inc., Austin, TX) and
stored at –80°C for RNA isolation. The sec-
ond mammary gland was whole mounted as
described previously (Markey et al. 2001a).
Uteri were dissected, blotted on filter paper,
and weighed. 
Morphometric analysis of mammary
glands. Slides were coded and analysis was per-
formed in a blind fashion. Mammary gland
images were captured with a Zeiss dissection
scope and AxioCam digital camera (Carl Zeiss
Inc., Germany). Morphometric analysis was
performed as described previously (Vandenberg
et al. 2006). The parameters examined include
number and area of terminal end buds (TEBs),
area subtended by the ductal tree, and ductal
extension measured as the distance from the
midpoint of the lymph node to the leading
edge of the ductal tree. In cases where the lead-
ing edge of the ductal tree did not grow beyond
the center of the lymph node, ductal extension
was given a negative value. 
RNA isolation and real-time quantitative
RT-PCR. Mammary gland RNA was isolated
and quantitative real time reverse transcription-
polymerase chain reaction (RT-PCR) was per-
formed as described previously (Munoz de
Toro et al. 2005). The primers used were
Msx2, forward: ggaagaccagatggaccaga, and
reverse: tctgtatcaagtggccctgtc; amphiregulin,
forward: aaggaggcttcgacaagaaa, and reverse:
atccgaaagctccacttcct; and ribosomal protein
L19 (a housekeeping gene), forward: atcgccaat-
gccaactcc, and reverse: tcatccttctcatccaggtca. 
Analysis of dose–response curves. For each
parameter, the following were calculated:
a) the lowest observable effect level (LOEL)
dose (the lowest dose causing a statistically sig-
nificant effect); b) the peak response [the
dose(s) at which the response reaches a plateau
or the highest response is achieved]; c) the
half-maximal dose (the amount of E2 inducing
half the maximal response); and d) the fold
change (the peak response divided by the
response of the ovariectomized control).
Curve-fitting analysis was performed for
each parameter to determine whether the
response to estradiol best conformed to a sig-
moidal (monotonic) curve, or to a polynomial
(inverted-U–shaped) curve. To determine
which responses could be considered statisti-
cally nonmonotonic, we assessed whether the
peak response of a given parameter occurred at
one of the intermediate doses and whether the
peak response could be statistically distin-
guished from the response at the highest dose.
When both criteria were met, the parameter of
interest was deﬁned as having a nonmonotonic
response to E2. 
Statistical analysis. Statistical signiﬁcance
was determined using SPSS software (SPSS,
Chicago, IL). To determine statistical differ-
ences between the responses at each dose or
the effects of BPA, we used nonparametric
Mann-Whitney U-tests as well as parametric
t-tests when data were normally distributed.
To compare the responses of CD-1 and
C57Bl6 mice, we used two-way analysis of
variance (ANOVA). Post hoc tests (Bonferroni
or planned t-tests) were used to make compar-
isons between groups. For all statistical tests,
results were considered signiﬁcant at p < 0.05.
Values in ﬁgures are mean ± SE. 
Results 
Effect of E2 on uterine weight. Uterine wet
weight represents the classical end point for
assessing estrogenicity. As expected, the uterus
demonstrated a monotonic dose–response
curve to E2 in both mouse strains at the doses
tested (Table 1, Figure 1A). We observed
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Table 1. Dose–response curves for uterine wet weight and mammary gland morphological parameters in both mouse strains.  
CD-1 Mice  C57Bl6 mice
Half-max Dose of Half-max Dose of
Parameter LOEL dose max effect Fold change Curve shape LOEL dose max effect Fold change Curve shape
Ductal extension 0.5 0.42 2.5–10 3.2 Inverted-U 2.5 0.6 1–50 –3.34 Inverted-U
No. of TEBs 2.5 1.8 5 9.8 Inverted-U 0.5 1.05 2.5–50 80.25 Inverted-U
TEB area 2.5 1.6 5 11.6 Inverted-U 1 1 2.5–50 97.44 Inverted-U
Ductal area 0.5 0.4 1–50 1.4 Inverted-U 2.5 0.78 1–50 3.3 Inverted-U
No. of TEBs/ductal area 2.5 2 5–10 7.0 —a 0.5 0.85 5–50 62.25 —a
TEB area/ductal area 2.5 1.6 2.5–10 8.6 —a 0.5 0.8 5–50 75.96 —a
Uterine weight 0.25 4.25 10–50 4.7 Monotonic 1.0 3.55 5–50 5.95 Monotonic
Uterine weight/bw 0.25 4.1 10–50 7.8 Monotonic 1.0 3.4 5–50 6.09 Monotonic
Msx2 2.5 2.5 5–50 4.7 Monotonic 0.5 1.5 5–50 10.6 Monotonic
Amphiregulin 1 3.6 5–50 64.8 Monotonic 2.5 4 5–50 81.81 Monotonic
max, maximal. The LOEL, half-maximal dose, dose of maximal effect, fold change, and curve shape were calculated.
aThe curve shape for these parameters is “derived” data, from a quotient between two direct measurements, each one of them being affected by E2; therefore, the shape of the derived
curve is irrelevant.significant differences between strains at E2
doses ≥ 0.5 µg/kg bw/day. However, because
CD-1 females are significantly larger than
their C57B16 counterparts (25.5 ± 0.2 g and
16.3 ± 0.2 g, respectively; p < 0.001), signiﬁ-
cant differences between strains were not
apparent when uterine weight was normalized
to body weight (not shown). When normal-
ized to the ovariectomized controls, the fold
change in uterine weight was also comparable
in both strains (Figure 1E). 
Morphometric parameters of the mam-
mary gland: response to E2. In CD-1 females,
E2 treatment increased the number and area
of TEBs (Table 1, Figure 1B) and increased
ductal extension (Figure 1C). Each of these
parameters revealed an inverted-U–shaped,
nonmonotonic response (Table 1). Graphic
representation of the ductal area also showed
an obvious inverted-U–shaped response to E2
(Figure 1D). 
In C57Bl6 females, we found that the
effect of E2 on the number of TEBs, area of
TEBs, ductal area, and ductal extension gener-
ated an inverted-U–shaped dose response
(Figure 1, Table 1). For every parameter, the
doses showing peak responses were similar to
those obtained in CD-1 females (Table 1). The
LOEL for the number and area of TEBs
occurred at a lower dose than in CD-1 females.
However, for ductal area and ductal extension,
the LOEL was found at a higher dose. 
When CD-1 and C57Bl6 responses were
compared, we detected no significant differ-
ences at any E2 dose for number or area of
TEBs. However, significant differences were
detected in parameters related to the overall
growth of the epithelium (i.e., ductal extension
and ductal area; Figure 1C–D). Because they
were detected even in ovariectomized females
(without E2 treatment), these differences
appeared to be largely due to the divergent
body size of these two strains. In fact, when
normalized to body weight, strain differences
only remained for ductal area; disparities
between strains disappeared for the other para-
meters (not shown). Finally, 2-way ANOVAs
did not indicate a signiﬁcant interaction vari-
able between E2 dose and mouse strain for any
mammary gland parameter, indicating that the
shape of the dose–response curves cannot be
statistically distinguished for CD-1 and
C57Bl6 strains. 
The number of TEBs per ductal area
(TEBs/area) and the area of all TEBs per duc-
tal area (TEB area/area) were calculated to
determine the TEB density. We found signiﬁ-
cant differences between these strains at 1, 10,
and 50 µg E2/kg bw/day regarding both TEB
density parameters (data not shown). At all
three doses, the response observed in C57Bl6
females was more pronounced than that in
CD-1 females. Because these parameters are
ratios of the number or area of TEBs (no
signiﬁcant differences shown between strains)
and ductal area (signiﬁcant differences shown
between strains, which correlate with animal
size), the overall response to E2 may be more
striking in the C57Bl6 strain because of their
smaller size and/or slower development. 
To explore this concept further, we nor-
malized the number and area of TEBs, ductal
area, and ductal extension to ovariectomized
controls. The mammary glands of ovariec-
tomized C57Bl6 mice displayed almost com-
plete developmental arrest, whereas those of
their CD-1 counterparts maintained a few
TEB structures. Accordingly, E2 treatment
increased the number of TEBs by 80-fold in
C57Bl6 and only 10-fold in CD-1 mice
(Figure 1F, Table 1), while the maximal TEB
number was similar (Figure 1B). The increase
in ductal extension was comparable in both
strains (Figure 1G, Table 1), whereas the
increase in ductal area was 1.4-fold in CD-1
and 3.3-fold in C57Bl6 mice (Figure 1H). 
Mammary gland gene expression: response
to E2. The expression of Msx2 and amphi-
regulin mRNAs, two estrogen-regulated genes
(Mallepell et al. 2006; Phippard et al. 1996),
increased monotonically with increasing
doses of E2 in both CD-1 and C57B16 mice
(Figure 2 and Table 1). 
Selection of doses for pubertal E2 chal-
lenge. To investigate the effects of perinatal
BPA exposure on the response to E2 at
Wadia et al.
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Figure 1. Estrogen dose–response curves (A–D) and the values for each parameter normalized to the ovariectomized control (E–H) for CD-1 and C57Bl6 mice.
Uterine weight (A, E), number of TEBs (B, F), ductal extension (C, G), and ductal area (D, H). Values shown are mean ± SE.
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CD-1
C57B16puberty, we used the dose–response curves of
the morphometric points described above to
identify two doses higher than the LOEL but
lower than the half-maximal response for each
strain. The half-maximal doses ranged from
0.40 to 2.0 µg E2/kg bw/day in CD-1 and 0.6
to 1.05 µg E2/kg bw/day in C57Bl6 mice
(Table 1). From these calculations, we chose
to administer an E2 challenge of 0, 0.5, or
1 µg/kg bw/day.
Morphometric analysis of the mammary
gland: response to BPA. In CD-1 females, the
number of TEBs increased with higher doses
of E2, as expected from the dose–response data.
However, after administration of 0.5 µg E2/kg
bw/day, the number of TEBs in 250BPA CD-1
mice increased signiﬁcantly over that observed
in 0BPA mice (Figure  3A). Other TEB para-
meters, such as the total area covered by TEBs
(Table 2), TEBs/area (Table 2), and TEB
area/ductal area (Figure 3B), were also
significantly enhanced by this treatment.
Additionally, the TEB area/area measured in
the 250BPA group treated with 1 µg E2/kg
bw/day was significantly lower (p < 0.015)
than that measured in the 0BPA treated with
the same dose of E2 (Figure 3B). When we
measured ductal length, there was a signiﬁcant
increase in 250BPA challenged with 1 µg
E2/kg bw/day compared with 0BPA mice
(Figure 3C). Additionally, increasing doses of
E2 administered to CD-1 mice induced overall
growth of the ductal epithelium, measured as
increased ductal area. However, perinatal expo-
sure to BPA had no effect on this parameter
(Table 2).
In C57Bl6 mice, the number of TEBs
increased with higher doses of E2, as expected
from the dose–response data. In 250BPA
females, the mean number of TEBs induced
by 0.5 µg E2/kg bw/day was increased com-
pared with 0BPA animals (Figure 3D), simi-
lar to the response seen in the CD-1 strain;
however, these differences were not statisti-
cally signiﬁcant, likely due to variability in the
data. Additionally, treatment with 1 µg E2/kg
bw/day induced significantly fewer TEBs in
250BPA compared with 0BPA females
(Figure 3D). The total TEB area induced by
administration of 1 µg E2/kg bw/day was lower
in the 250BPA mice compared with 0BPA
animals (Table 2), although this decrease was
not statistically signiﬁcant. As in CD-1 mice,
TEB parameters such as TEBs/area (Table 2)
and TEB area/area (Figure 3E) were signifi-
cantly lower in the 250BPA mice treated with
1 µg E2/kg bw/day compared with 0BPA in
C57Bl6 mice.
Parameters associated with overall ductal
growth (ductal area and extension) were also
measured in the C57Bl6 mammary gland. As
expected, higher doses of E2 induced larger
areas (Table 2) and greater ductal extensions
(Figure 3F) than in ovariectomized controls. As
observed in CD-1 mice, perinatal exposure to
BPA did not alter ductal area; BPA also did not
alter ductal extension in C57Bl6, contrasting
with growth patterns observed in CD-1 mice. 
Uterine weight: response to BPA. As
expected, treatment with increasing doses of
E2 resulted in increased uterine wet weight. In
Strain differences and the response to estrogens
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Figure 2. Gene expression in CD-1 and C57Bl6 mice. Expression of (A) Msx2 and (B) amphiregulin mRNA in
the mammary glands was quantiﬁed using real-time RT-PCR. The values (mean ± SE) are fold change with
respect to a calibrator sample.
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Fboth strains, perinatal treatment with 250 ng
BPA/kg bw/day did not alter this parameter
(Table 2). 
Discussion
In the present study we examined two impor-
tant issues regarding estrogen action—strain
sensitivity and dose–response curve shape—
always in the context of the effects of perina-
tal BPA exposure. Previously, we reported
that perinatal exposure to environmentally
relevant levels of BPA results in altered post-
natal development of the mammary gland
(Markey et al. 2001a, 2003a; Munoz de Toro
et al. 2005). One of the most striking obser-
vations was that the sensitivity of the mam-
mary gland to E2 increased in perinatally
BPA-exposed CD-1 females that were
ovariectomized before puberty (Munoz de
Toro et al. 2005). The present study revealed
that both outbred CD-1 and inbred C57Bl6
strains respond quite similarly to E2 and BPA
in many parameters. The C57Bl6 strain is of
particular interest because it is widely used to
study mammary gland development and in
the generation of genetically modiﬁed mice. 
There are concerns regarding the use of
laboratory strains selected for large litter size
(i.e., CD-1 mice) stemming from the possible
correlation with resistance to endocrine dis-
ruptors including xenoestrogens. It has been
suggested that testing chemicals in these
strains may underestimate the endocrine dis-
ruptor potential of the agent being examined
(Spearow et al. 1999). Specifically, CD-1
males were shown to be E2-resistant when
compared with C57Bl6 mice regarding effects
on testes weight and spermatogenesis
(Spearow et al. 1999). Strain susceptibility
was also observed in rats, often speciﬁc to the
chemical being studied. For example,
Sprague-Dawley rats were resistant to BPA
compared with the Fischer 344 rats regarding
proliferation of vaginal epithelium. However,
both strains responded equally to E2. Thus,
the differences between Sprague-Dawley and
Fischer 344 rats suggest that there may be
strain-specific differences that affect the
metabolism of a particular estrogenic chemi-
cal or class of chemicals (Long et al. 2000). 
The shape of the dose–response curve
should also be considered when assessing strain
sensitivity. When a given parameter exhibits a
monotonic dose–response curve, all effective
doses should result in a qualitatively similar
effect. To the contrary, if the dose–response
curve is nonmonotonic or has an inverted-U
shape, opposite effects might be observed at
different doses. It has been proposed that non-
monotonic dose–response curves are generated
by the integration of two or more monotonic
dose–response curves that are occurring
through different pathways and affecting a
common end point with opposing effects
(Conolly and Lutz 2004). For those end
points, one cannot test a single high dose of a
given chemical to assess whether or not it pro-
duces a biological effect (vom Saal and Hughes
2005; Welshons et al. 2003). In the present
study, morphometric parameters of the mam-
mary glands of both CD-1 and C57Bl6 mice
displayed inverted-U–shaped dose–response
curves to E2. Although most parameters in
CD-1 mice met the criteria for statistical non-
monotonicity, variability in responses pre-
vented the C57Bl6 from meeting this
standard. One striking difference between
these strains was the state of quiescence of the
mammary gland of C57Bl6 ovariectomized
mice compared with their CD-1 counterparts.
There were practically no TEBs in the former,
whereas a few TEBs were present in the CD-1
females 10 days after ovariectomy. It is possible
that these results are indicative of different rates
of development or onset of puberty in females
of these two strains. Although there is no evi-
dence in the literature to support this conclu-
sion, no studies have examined age of puberty
in these two strains under the same conditions
(food supplied, light cycle, temperature, etc.)
In the present study, females were ovariec-
tomized before puberty, and thus this informa-
tion could not be collected.
In contrast to the morphometric parame-
ters, the induction of estrogen-target genes in
the mammary gland was monotonic in both
strains. The magnitude of the response was
comparable in the two strains, and the sensitiv-
ities of these responses were lower than those of
several morphological end points. 
E2 sensitivity of the uterus. Diel et al.
(2004) found that the uterus and vagina of sev-
eral rat strains responded similarly to three dif-
ferent doses of estrogen in a 3-day assay (Diel
et al. 2004). In the present study, we arrived at
a similar conclusion using a set of seven differ-
ent E2 doses and a 10-day assay in mice. Both
mouse strains displayed a monotonic dose–
response curve regarding uterine weight at the
doses tested, and their response was comparable
when uterine weight was normalized to body
weight. Similar dose–response curves were
reported in a 3-day (Padilla-Banks et al. 2001)
and a 10-day mouse assay (Skarda 2002).
Overall, this study revealed little or no
difference in the sensitivity to E2 between
CD-1 and C57Bl6 mice regarding the utero-
trophic response and a variety of morphomet-
ric and gene-expression end points in the
mammary gland. This is in contrast to the
marked differences observed between these
strains in testis end points (Spearow et al.
1999). The mechanisms underlying the latter
differences have yet to be determined.
However, steroid metabolism by the liver is
subject to hormonal imprinting (Gustafsson
et al. 1977), which may explain differences in
response between males and females of the
same strain. 
Effect of perinatal exposure to BPA on the
pubertal response to E2. Perinatal BPA expo-
sure did not alter the uterine response to E2
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Table 2. Mammary gland morphological parameters of CD-1 and C57Bl6 mice exposed perinatally to BPA (0BPA and 250BPA) and postnatally to 0, 0.5, or 1 µg
E2/kg bw/day. 
E2 (µg/kg bw/day), BPA 
Treatment 0, 0BPA 0, 250BPA 0.5, 0BPA 0.5, 250BPA 1, 0BPA 1, 250BPA
CD-1 mice
Ductal extension 2.62 ± 0.63a 2.80 ± 0.76a 4.41 ± 0.74a,b 4.69 ± 0.58a,b 4.54 ± 0.53a 6.00 ± 0.46b
# TEBs 1.4 ± 0.58a 2.1 ± 0.78a 5.5 ± 1.2b 10.0 ± 0.65c 11.9 ± 1.3c 10.1 ± 0.50c
TEB area 0.048 ± 0.020a 0.078 ± 0.029a 0.219 ± 0.054b 0.428 ± 0.040d 0.546 ± 0.049c 0.440 ± 0.034c,d
Ductal area 79.1 ± 8.7a 82.26 ± 7.0a 126.1 ± 9.2b 118.6 ± 8.2b 124.58 ± 8.65b 139.8 ± 6.8b
# TEBs/ductal area 0.015 ± 0.006a 0.023 ± 0.008a 0.042 ± 0.009a 0.085 ± 0.006b 0.096 ± 0.009b 0.075 ± 0.005b
TEB area/ductal area 0.0005 ± 0.0002a 0.0009 ± 0.0003a 0.0017 ± 0.0004a 0.0036 ± 0.0003b,c 0.0045 ± 0.0004b 0.0032 ± 0.0002c
Uterine weight 15.32 ± 1.58a 14.97 ± 0.73a 20.59 ± 1.02b 19.46 ± 0.91b 25.47 ± 1.46b,c 28.32 ± 1.33c
C57Bl6 mice
Ductal extension –3.00 ± 0.34a –2.39 ± 0.93a 0.99 ± 0.34b 1.68 ± 0.59b 2.13 ± 0.25b 2.05 ± 0.36b
# TEBs 0.0 ± 0.0a 0.0 ± 0.0a 3.1 ± 0.6b 7.7 ± 4.0a,b,c 10.1 ± 1.1c 6.0 ± 0.8a,b
TEB area 0.00 ± 0.00a 0.00 ± 0.00a 14.57 ± 2.72a 36.83 ± 16.21a 54.14 ± 8.23b 30.50 ± 5.98a,b
Ductal area 6.40 ± 0.80a 10.10 ± 2.64a 29.13 ± 1.33b 36.03 ± 4.49b,c 40.58 ± 3.41c 44.69 ± 2.06c
# TEBs/ductal area 0.00 ± 0.00a 0.00 ± 0.00a 0.11 ± 0.019b 0.18 ± 0.072a,b,c 0.25 ± 0.018c 0.13 ± 0.015a,b
TEB area/ductal area 0.00 ± 0.00a 0.00 ± 0.00a 0.44 ± 0.080b 0.91 ± 0.31a,b,c 1.34 ± 0.16c 0.67 ± 0.12a,b
Uterine weight 5.1 ± 0.26 a 8.05 ± 2.6a,b 9.31 ± 0.71b 11.00 ± 1.58b,c 12.20 ± 0.76c 13.0 ± 1.53c
Letters that are not in common indicate signiﬁcant differences (p < 0.05).administered from PND25 to PND35 in
either mouse strain. In contrast, the response
of the mammary gland to E2 was signiﬁcantly
altered by perinatal BPA exposure. A pattern
emerged for TEB-related parameters, which
increased in response to 0.5 µg E2/kg bw/day
relative to controls, suggesting a shift to the
left of the dose–response curve. Increased
responses at 0.5 µg E2/kg bw/day were signiﬁ-
cant in CD-1 mice but did not reach signiﬁ-
cance in C57Bl6. The increase in number of
TEBs induced by 1 µg E2/kg bw/day was sig-
nificantly reduced in the BPA-pretreated
C57Bl6 mice. These results suggest a differ-
ence between the two strains in the level of the
response to E2 after perinatal BPA exposure,
such that increased sensitivity to E2 was mani-
fested at a lower dose in CD-1 than in
C57Bl6 mice. Alternatively, the sensitivity of
the two strains may be similar, but the higher
variability in the C57Bl6 TEB-related parame-
ters may have precluded reaching statistical
significance for end points that were signifi-
cantly altered in the CD-1 strain. However, in
both strains perinatal exposure to BPA signiﬁ-
cantly altered the response to E2 later in life.
Estrogen exposure represents a main risk
factor for breast carcinogenesis. Increased sensi-
tivity to E2 may have similar effects. Consistent
with this concept, previous studies of CD-1
mice exposed perinatally to BPA revealed an
increased number of TEBs at puberty and ter-
minal ends in adulthood (Markey et al. 2001a;
Munoz de Toro et al. 2005). These two struc-
tures are thought to be the sites where neo-
plasias arise. Also, there is an overexpression of
progesterone receptors in BPA-exposed ani-
mals, which in turn induces excessive lateral
branching of the mammary gland ducts
(Munoz de Toro et al. 2005), resulting in an
increased ductal density of the gland. In
humans, increased mammographic density is
also a risk factor for breast cancer (McCormack
and dos Santos Silva 2006). In the present
study we extend these findings to C57Bl6
mice, suggesting that the enhanced sensitivity
to E2 resulting from perinatal BPA exposure
may represent a general phenomenon in mice
rather than a strain idiosyncrasy.
Nonmonotonic dose–response curves.
In vitro studies that used human breast epithe-
lial cells and other estrogen-target cell lines
showed nonmonotonic dose–response curves in
response to increasing E2 doses (Amara and
Dannies 1983; Soto and Sonnenschein 1985).
This type of curve suggests that estrogens can
evoke different effects, such as induction (Soto
and Sonnenschein 1987) or inhibition of cell
proliferation (Szelei et al. 2000), depending on
the dose tested. The combined effect of these
variable responses is reﬂected in the overall cell
number (Soto and Sonnenschein 2001). In the
mammary gland, estrogens promote prolifera-
tion—manifested as ductal growth (Nandi
1958)—and induce apoptosis—manifested as
lumen formation (Munoz de Toro et al. 2005). 
Conclusions
Nonmonotonic dose–response curves are
observed in cultured cells and in animal mod-
els, and are oftentimes observed for endocrine
end points. These patterns highlight the unre-
liability of assuming that the effect of exposure
to low doses of a hormone, endocrine disrup-
tor, or other toxicant can be extrapolated from
the response to high doses of the compound
(Conolly and Lutz 2004; vom Saal and
Hughes 2005). 
Contrary to the clear differences in the tes-
ticular response to postnatal administration of
E2 between CD-1 and C57Bl6 mice (Spearow
et al. 1999), the differences observed in the
uterus and mammary gland of these different
mouse strains are subtle. In addition, the mam-
mary glands of both strains are sensitive to
perinatal exposure to low doses of BPA, in that
the postnatal response to E2 is significantly
modiﬁed. This observation suggests that both
strains provide adequate models for the study
of perinatal exposure to xenoestrogens. Even
though the outbred CD-1 strain has been
selected for large litter size and reproductive
efficiency, these results show that this strain
provides an excellent model for the study of
estrogen action in the uterus and mammary
gland. Additionally, mice of the C57Bl6 strain
may be used advantageously in the study of
endocrine disruption when an inbred strain is
required. Conﬁrmation of the suitability of the
C57Bl6 strain for this work is important
because many genetically modified animals
have been developed on this background. 
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